An investigation of the constancy of effect in Cochrane systematic reviews in context with the assumptions for noninferiority trials
Abstract When designing a noninferiority (NI) study one of the most important steps is to set the noninferiority (NI) limit. The NI limit is an acceptable loss of efficacy for a new investigative treatment compared to an active control treatment – often standard care. The limit should be a value so...
Main Authors: | Enass M. Duro, Steven A. Julious, Shijie Ren |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-07-01
|
Series: | BMC Medical Research Methodology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12874-022-01684-9 |
Similar Items
-
Understanding superiority, noninferiority, and equivalence for clinical trials
by: Kamal Kishore, et al.
Published: (2020-01-01) -
Understanding noninferiority trials
by: Seokyung Hahn
Published: (2012-11-01) -
The normality assumption on between-study random effects was questionable in a considerable number of Cochrane meta-analyses
by: Ziyu Liu, et al.
Published: (2023-03-01) -
The Quality of Randomized Controlled Trial in Cochrane Kidney and Transplant Group
by: Hanieh Salehi-Pourmehr, et al.
Published: (2021-12-01) -
Randomized, noninferiority trial evaluating the efficacy of a novel teat sealant in pasture grazed dairy cows
by: P. Mehrtens, et al.
Published: (2023-12-01)